Medifast (NYSE:MED) Shares Cross Above 200 Day Moving Average – Time to Sell?

Medifast Inc (NYSE:MED)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $11.23 and traded as high as $11.57. Medifast shares last traded at $11.0690, with a volume of 344,977 shares traded.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Medifast from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $12.00.

Medifast Price Performance

The stock has a market capitalization of $123.09 million, a PE ratio of -6.05 and a beta of 0.62. The business’s fifty day moving average price is $11.84 and its 200-day moving average price is $11.23.

Medifast (NYSE:MED) last released its quarterly earnings data on Monday, May 4th. The specialty retailer reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36. The company had revenue of $76.04 million during the quarter, compared to analyst estimates of $69.20 million. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. On average, analysts expect that Medifast Inc will post -1.97 earnings per share for the current fiscal year.

Insider Activity at Medifast

In other news, Director Scott Schlackman purchased 2,500 shares of Medifast stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $12.53 per share, for a total transaction of $31,325.00. Following the transaction, the director directly owned 30,549 shares of the company’s stock, valued at approximately $382,778.97. This trade represents a 8.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medifast

Large investors have recently added to or reduced their stakes in the business. Lido Advisors LLC purchased a new position in Medifast during the third quarter worth about $4,521,000. Steamboat Capital Partners LLC purchased a new position in shares of Medifast during the fourth quarter worth about $2,952,000. Charles Schwab Investment Management Inc. increased its position in shares of Medifast by 30.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock worth $8,297,000 after purchasing an additional 181,618 shares during the last quarter. Bank of America Corp DE increased its position in shares of Medifast by 37.4% in the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock worth $5,569,000 after purchasing an additional 107,854 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Medifast in the third quarter valued at approximately $867,000. Institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.